{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T12:57:35Z","timestamp":1743080255864,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":11,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071631744"},{"type":"electronic","value":"9781071631751"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-3175-1_38","type":"book-chapter","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T07:02:13Z","timestamp":1684479733000},"page":"589-595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Measuring Emicizumab Levels in the Hemostasis Laboratory"],"prefix":"10.1007","author":[{"given":"Geoffrey","family":"Kershaw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Dix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,20]]},"reference":[{"key":"38_CR1","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/nm.2942","volume":"18","author":"T Kitazawa","year":"2012","unstructured":"Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T et al (2012) A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 18:1570\u20131574","journal-title":"Nat Med"},{"key":"38_CR2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","volume":"379","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME et al (2018) Emicizumab prophylaxis in patients who have Hemophilia A without inhibitors. N Engl J Med 379:811\u2013822","journal-title":"N Engl J Med"},{"key":"38_CR3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","volume":"377","author":"J Oldenburg","year":"2017","unstructured":"Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G et al (2017) Emicizumab prophylaxis in Hemophilia A with inhibitors. N Engl J Med 377:809\u2013818","journal-title":"N Engl J Med"},{"key":"38_CR4","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1055\/s-0037-1615358","volume":"80","author":"C Rothschild","year":"1998","unstructured":"Rothschild C, Laurian Y, Satre EP, Borel Derlon A, Chambost H, Moreau P et al (1998) French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 80:779\u2013783","journal-title":"Thromb Haemost"},{"key":"38_CR5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","volume":"9","author":"J Wight","year":"2003","unstructured":"Wight J, Paisley S (2003) The epidemiology of inhibitor in haemophilia A: a systematic review. Haemophilia 9:418\u2013435","journal-title":"Haemophilia"},{"key":"38_CR6","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1055\/s-0039-1692427","volume":"119","author":"J Muller","year":"2019","unstructured":"Muller J, Pekrul I, Potzsch B, Berning B, Oldenburg J, Spannagl M (2019) Laboratory monitoring in Emicizumab-treated persons with Hemophilia A. Thromb Haemost 119:1384\u20131393","journal-title":"Thromb Haemost"},{"key":"38_CR7","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/hae.13990","volume":"26","author":"A Bowyer","year":"2020","unstructured":"Bowyer A, Kitchen S, Maclean R (2020) Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors. Haemophilia 26:536\u2013542","journal-title":"Haemophilia"},{"key":"38_CR8","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.3324\/haematol.2021.278579","volume":"106","author":"A Harroche","year":"2021","unstructured":"Harroche A, Sefiane T, Desvages M, Borgel D, Lasne D, Casari C et al (2021) Non-inhibitory antibodies inducing increased emicizumab clearance in a severe hemophilia a inhibitor patient. Haematologica 106:2287\u20132290","journal-title":"Haematologica"},{"key":"38_CR9","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1111\/jth.15506","volume":"19","author":"M Keneda","year":"2021","unstructured":"Keneda M, Kawasaki R, Matsumoto N, Abe H, Tashiro Y, Inokuchi Y et al (2021) Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia a. J Thromb Haemost 19:2938\u20132946","journal-title":"J Thromb Haemost"},{"key":"38_CR10","unstructured":"Emicizumab Calibrator package inert. Revision 02\/22\/2021, r2 Diagnostics"},{"key":"38_CR11","doi-asserted-by":"publisher","unstructured":"Kershaw G, Dix C, Chen VM, Cai N, Khoo TL (2022) Emicizumab assay evaluations and results from an Australian field study of emicizumab measurement. Pathology 54(6):755\u2013762. https:\/\/doi.org\/10.1016\/j.pathol.2022.02.006","DOI":"10.1016\/j.pathol.2022.02.006"}],"container-title":["Methods in Molecular Biology","Hemostasis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3175-1_38","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T07:06:54Z","timestamp":1684480014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3175-1_38"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9781071631744","9781071631751"],"references-count":11,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3175-1_38","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"20 May 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}